If you want the shortest honest answer: manufacturer savings can help in 2026, but only if you are using the right program for your situation. As of October 2026, the official pages for Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo all advertise a $25 price for eligible commercially insured patients. But those are not universal coupons. Each card caps how much it saves, the cards exclude government beneficiaries, and they do not stack with other discount programs. [1] [2] [3] [5] [11]

All prices in this article are tracked in our monthly GLP-1 Price Index.

The second thing readers miss is that a savings card is not the same as patient assistance. A savings card lowers what an eligible patient pays at the pharmacy. A patient assistance program is a separate no-cost route with income and insurance gates, it usually takes more paperwork, and Novo Nordisk’s 2026 program does not include Wegovy at all. [6] [9] [10]

If you want the broader access picture first, read our insurance guide, cheapest-way guide, Medicare coverage guide, and Ozempic vs. Mounjaro comparison.

Not sure you are getting the best price? Check the cheapest legal path for your situation:

Which GLP-1 Savings Program Fits Your Situation?

Use this before you click any coupon page:

Your situationBest first stepWhy
You have commercial insurance and the drug is coveredTry the official manufacturer savings page first. [1] [2] [3] [5] [11] This is the group those $25 offers are built for, up to each card’s savings cap.
You have commercial insurance, but coverage is unclearCheck coverage first, then the savings page. [1] [5] The card helps most when the plan already covers the drug. Lilly also lists card prices for commercial plans that do not cover Zepbound, Mounjaro, or Foundayo. [3] [4] [11]
You are self-pay and want brand medicationCheck the official self-pay pricing, not random coupon sites. [1] [2] [3] [11] Self-pay offers exist, but they are dose-specific, and several intro prices end December 31, 2026.
You have Medicare, Medicaid, VA, or TRICAREDo not assume the savings card applies. If you have Part D, check the Medicare GLP-1 Bridge; otherwise compare self-pay pricing. [1] [2] [5] [12] Government beneficiaries are excluded from these card offers.
You are uninsured and low incomeCheck patient assistance separately, knowing Novo Nordisk’s 2026 program covers Ozempic, not Wegovy. [6] [9] [10] That is the real no-cost lane for Ozempic, and it is not the same as a coupon.

What Does Each Manufacturer Savings Offer Cover in 2026?

Wegovy

Wegovy’s official page splits the offer into two lanes. For eligible commercially insured patients, the page says they can pay as little as $25 per month, subject to a maximum savings of $100 a month, for either the pen or the pill. On the self-pay side, new patients using the lower starter pen doses can pay $199 per month for the 0.25 mg and 0.5 mg doses for two monthly fills through December 31, 2026, then $349 per month for 0.25 mg through 2.4 mg and $399 per month for the Wegovy HD 7.2 mg pen. Self-pay Wegovy pills cost $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg. [1]

That is useful, but it is not a universal coupon. The cap matters: if your plan copay is $200, a $100 maximum saving still leaves you paying about $100. The same page says the insured offer excludes government beneficiaries, the self-pay pricing varies by dose, and Novo Nordisk can change or cancel the program at any time. [1]

Ozempic

Ozempic’s savings page follows the same basic pattern, but with diabetes-specific dosing and pricing. For commercially insured patients with coverage, the page says they can pay as little as $25 for up to a 3-month prescription, saving up to $100 a month for up to 48 months. For self-pay pens, it lists $199 per month for the first two months of 0.25 mg or 0.5 mg for new patients (offer through December 31, 2026), then $349 per month for 0.25 mg, 0.5 mg, or 1 mg, and $499 per month for 2 mg. The page also lists an Ozempic pill, with self-pay prices of $149 (1.5 mg), $199 (4 mg), and $299 (9 mg) a month. [2]

That distinction matters because a lot of readers see the intro number and assume that is the long-term cash price. It is not. The official page makes clear that the lower self-pay amount is a limited-time intro pathway rather than the ongoing price for every dose and every patient. [2]

Zepbound

If you are looking at weight-loss tirzepatide rather than diabetes tirzepatide, the relevant official savings page is Zepbound, not Mounjaro. Lilly’s Zepbound page has two separate lanes. If your commercial plan covers the Zepbound single-dose pen, the savings card can bring a 1-, 2-, or 3-month fill to as little as $25, with savings capped at $100 per month of supply and $1,300 per calendar year. [3]

The self-pay lane, and the card offer for commercial plans that do not cover Zepbound, is priced by dose for the KwikPen or vials: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg. The $449 price on 7.5 mg and up applies only if each refill is completed within 45 days of the previous delivery; otherwise the regular price is $499 for 7.5 mg and $699 for 10 mg to 15 mg. [3]

That clarity is useful, but you still have to read the restrictions. The page says the card savings cannot be combined with other discount programs, that government beneficiaries are excluded, and that card savings end on December 31, 2026 under the current terms. Lilly’s page also says Zepbound coverage has been restored on select CVS Caremark formularies. [3]

Mounjaro

Mounjaro is the tirzepatide brand used on the diabetes side, so its savings page is not interchangeable with Zepbound’s. As of October 2026, the Mounjaro page says eligible patients may pay as little as $25 for up to a 3-month prescription, and if insurance does not allow 3-month fills, the card can still be used for a 1-month prescription. Savings are capped at $150 for a one-month fill ($450 for three months) and $1,950 per calendar year, and the card expires December 31, 2026. If a commercial plan does not cover Mounjaro, the card can bring a one-month fill to as low as $499. [4]

The current FAQ adds the most important qualifier: eligible, commercially insured patients with Mounjaro coverage can pay as little as $25 for up to a 3-month prescription, and governmental beneficiaries are excluded. [5]

Foundayo

Foundayo (orforglipron) is Lilly’s once-daily GLP-1 pill, and it has its own savings card. Eligible commercially insured patients whose plan covers Foundayo can pay as little as $25 for a 1-, 2-, or 3-month fill, with savings capped at $100 a month and $1,000 a year, and the card expires December 31, 2026. Self-pay prices are $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, and $299 at 9 mg and above; the 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026. [11] For where to fill it, see where to get Foundayo.

That is the pattern across this category: manufacturer savings can be excellent, but the official pages are aiming at a narrower group than “anyone who wants a coupon.”

Is a Savings Card the Same as Patient Assistance?

If you are uninsured or your insurance is unusable, you may not need a savings card at all. You may need a patient assistance program, which is a different lane entirely.

Novo Nordisk’s current Patient Assistance Program page says the program provides medicine at no cost to qualifying patients and that there is no registration charge or monthly fee. But the same page also says patients with private or commercial insurance are not eligible. [6]

The bigger limit is the product list. Novo Nordisk’s 2026 PAP product list includes Ozempic (for uninsured patients only), several insulins, Xultophy, and supplies. It does not include Wegovy, so there is no Novo Nordisk PAP route to free Wegovy in 2026. [10]

This is where people get confused. A savings card lowers a fill at the pharmacy. A PAP helps a narrower patient get medication at no cost after income and insurance screening. Those are not interchangeable programs. [6]

The current NovoCare PAP page also makes the rules more specific than many roundup articles do:

  • It says applicants must have qualifying household income and either Medicare or no insurance. [6]
  • It says Medicare beneficiaries with prescription drug coverage will no longer be eligible to receive Ozempic through the PAP. [6]
  • It says uninsured Ozempic patients can still have access through the PAP, but their household income must be at or below 200% of the federal poverty level. [6]
  • For Novo Nordisk’s other covered products, such as insulins, the limit for uninsured patients is 400% of the federal poverty level. [6]

Using the current HHS 2026 poverty-guideline table for the 48 contiguous states and D.C., that means:

  • Household of 1: base guideline $15,960, so 200% FPL = $31,920 (the Ozempic limit) and 400% FPL = $63,840. [9]
  • Household of 4: base guideline $33,000, so 200% FPL = $66,000 and 400% FPL = $132,000. [9]

Alaska and Hawaii use higher separate guideline tables, so do not use the contiguous-state figures if you live there. [9]

The practical lesson is simple: if you need a true $0 route for Ozempic, stop searching for “coupon” and start checking whether you meet a real PAP screen. For Wegovy, the lowest verified options are the savings card if you have commercial coverage, the Medicare GLP-1 Bridge if you have Part D, or self-pay pricing. [1] [10] [12]

Can You Use These Offers With Insurance, GoodRx, or Medicare?

With commercial insurance

This is the most coupon-friendly group. Wegovy, Ozempic, Mounjaro, Zepbound, and Foundayo all frame their best savings language around eligible commercially insured patients, and Mounjaro explicitly ties the $25 language to patients with coverage. [1] [2] [3] [5] [11]

In other words, these programs are often designed to reduce a covered copay, not to replace the insurance benefit entirely.

With Medicare, Medicaid, or other government coverage

The current Wegovy and Ozempic savings pages exclude government beneficiaries, and the Mounjaro FAQ uses the same exclusion language. [1] [2] [5] Lilly’s Zepbound and Foundayo cards exclude Medicare, Medicaid, and other government-funded plans as well. [3] [11]

So if you have Medicare, Medicaid, VA, or TRICARE, do not start by assuming the manufacturer savings card will apply. Two other routes exist in 2026:

  • Medicare GLP-1 Bridge: eligible Part D enrollees pay $50 a month for Wegovy (pen or pill), the Zepbound KwikPen, or Foundayo from July 1, 2026 through December 31, 2027, with BMI rules and a prior authorization. People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are not eligible for the Bridge, but Medicare says their Part D plan might cover a GLP-1. [12] [13] Our Medicare GLP-1 Bridge checklist walks through it.
  • Self-pay offers: NovoCare’s terms allow people with government coverage to choose self-pay, and Lilly lists self-pay pricing for people with Medicare or other government coverage. The purchase then happens outside your plan and does not count toward your deductible or out-of-pocket limit. [2] [3] [7]

With GoodRx or another discount card

Do not assume coupon stacking works. NovoCare’s current pharmacy terms say the offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or similar offer. Lilly’s current Zepbound savings language says the card savings cannot be combined with other discount programs either. [3] [7]

TrumpRx.gov lists the same Wegovy, Ozempic, and Zepbound self-pay prices as the manufacturer pages, so it is another way to reach the same price, not a second discount on top of it. [14]

That means the real-world rule is:

Compare the manufacturer offer against the other discount option. Do not expect both to apply to the same fill.

Will the cheaper fill help my deductible?

Not always. Ozempic’s current official terms say that self-pay offers processed outside insurance will not count toward deductibles and cannot be applied to insurance maximum out-of-pocket limits. [8]

That matters more than most coupon articles admit. A lower price today may not help your annual benefit math if it bypasses insurance.

Step-by-Step: How to Use a Manufacturer Savings Offer Without Wasting a Refill

  1. Confirm the exact drug and brand. Wegovy and Ozempic are semaglutide brands, but they are not the same program. Zepbound and Mounjaro are tirzepatide brands, but they are not the same program either. Foundayo has its own Lilly card. [1] [2] [3] [5] [11]
  2. Check whether you are in the right insurance bucket. Commercial insurance is the main target for the best savings-card offers. Government coverage usually is not. [1] [2] [5]
  3. Read the official terms, not just the banner price. The banner tells you the best-case number. The terms tell you whether you qualify, how much the card can save, whether the offer expires, and whether it helps your deductible. [3] [7] [8]
  4. Use the manufacturer’s support line if the pharmacy rejects it. Wegovy lists a dedicated savings-offer support number and pharmacy help desk, while Mounjaro directs patients to Lilly Support Services. [1] [4]
  5. If you are uninsured and low income, check PAP early for Ozempic. Do not spend days trying to force a retail coupon into a no-insurance problem, and know that Wegovy is not on Novo Nordisk’s 2026 PAP list. [6] [9] [10]

The Most Honest Decision Checklist

Use this if you just want the next right move:

  • Wegovy with commercial coverage: Start with the official Wegovy savings page, and check whether your copay is above the $100 monthly savings cap. [1]
  • Ozempic with commercial coverage: Start with the official Ozempic savings page, but do not assume the intro self-pay offer is your long-term price. [2]
  • Weight-loss tirzepatide: Use the Zepbound savings page, not the Mounjaro one. The $25 card is for the single-dose pen; KwikPen and vial prices are separate. [3]
  • Diabetes tirzepatide: Use the Mounjaro savings page and verify that your plan actually covers the drug. [4] [5]
  • Foundayo: Use the Foundayo savings page; the card and the temporary self-pay prices both run through December 31, 2026 under current terms. [11]
  • No insurance and low income: Check patient assistance for Ozempic, not coupon blogs. Wegovy is not on Novo Nordisk’s 2026 PAP list. [6] [9] [10]
  • Medicare Part D: Check the Medicare GLP-1 Bridge first; the standard savings cards exclude government beneficiaries. [1] [2] [12] [13]
  • Medicaid: Assume the standard savings card may not apply until the official page proves otherwise. [1] [2] [5]
  • Planning to stack GoodRx with a manufacturer offer: Expect that to fail unless the current terms explicitly allow it. [3] [7]

Bottom Line

The best way to think about GLP-1 manufacturer coupons in 2026 is this:

  • Savings cards are real and useful, but mostly for eligible commercially insured readers, and each card caps how much it saves.
  • Self-pay offers can still help, but they are dose-based, and several intro prices end December 31, 2026.
  • Patient assistance is the true no-cost lane for Ozempic, but it is a separate program with tighter rules, and it does not include Wegovy.

The right question is not “Is there a coupon?” It is:

Which lane am I actually in: covered commercial insurance, Medicare, self-pay brand pricing, or real patient assistance?

Once you answer that, the official manufacturer pages start making a lot more sense.